~89 spots leftby Dec 2027

Family Support Program for Critical Illness

Recruiting in Palo Alto (17 mi)
+2 other locations
HP
Wendy G Lichtenthal Miller School of ...
Overseen byWendy Lichtenthal, PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Recruiting
Sponsor: Weill Medical College of Cornell University
Disqualifiers: Cognitive impairment, Suicidal ideation, others
Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial tests EMPOWER, a psychological therapy designed to help family members who make medical decisions for critically ill patients in ICUs. The therapy aims to reduce grief and stress by teaching coping strategies that help people accept and manage their emotions. Researchers hope this will improve mental health outcomes and decision-making abilities for these family members.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems focused on supporting decision-makers rather than changing medication regimens.

What data supports the effectiveness of the treatment EMPOWER for critical illness?

Research shows that the EMPOWER program, which is a cognitive-behavioral and acceptance-based treatment, helps improve mental health for those making medical decisions for critically ill patients. Similar programs, like COPE, have been effective in reducing stress and improving coping for parents of critically ill children, suggesting that EMPOWER may also be beneficial.12345

Is the Family Support Program for Critical Illness safe for humans?

The EMPOWER intervention, which is part of the Family Support Program for Critical Illness, has been evaluated for its feasibility and acceptability, suggesting it is generally safe for surrogate decision-makers of critically ill patients.12467

How is the EMPOWER treatment different from other treatments for critical illness?

The EMPOWER treatment is unique because it is a cognitive-behavioral, acceptance-based intervention specifically designed for surrogate decision-makers of critically ill patients in the ICU. It focuses on improving both the mental health of the surrogates and the quality of life for patients, which is not typically addressed by standard medical treatments for critical illness.248910

Research Team

Wendy G Lichtenthal Miller School of ...

Wendy Lichtenthal, PhD

Principal Investigator

University of Miami

HP

Holly Prigerson, PhD

Principal Investigator

Weill Medical College of Cornell University

Eligibility Criteria

This trial is for adult surrogate decision-makers of critically ill ICU patients near end-of-life. They must speak English, be able to use a device with internet, and live where the interventionist is licensed. Participants need to show significant pre-loss grief or distress but can't have cognitive impairments or recent suicidal ideation.

Inclusion Criteria

Surrogate decision-makers whom physicians or advance practice providers indicate as the designated health care proxy or decision-making patient surrogates, or who are listed as such in the patient's medical charts or by self-report of the surrogate
Surrogate decision-makers will need to be willing to utilize a device (computer, tablet, phone) with internet
My surrogate decision-maker speaks English.
See 5 more

Exclusion Criteria

Surrogate-decision makers who endorse suicidal ideation in the past month based on responses to the Columbia Suicide Severity Rating Scale
Surrogate-decision makers who are unable to access a functional device for videoconferencing and decline the offer to use a study loner device
Patients and surrogate decision-makers who do not meet the eligibility criteria
See 1 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive the EMPOWER intervention or Supportive Conversation over a period of 3 months

3 months
Up to 4 visits (in-person and by phone)

Follow-up

Participants are monitored for changes in symptoms of PTSD, PGD, and other outcomes

12 months
Assessments at 3 months and 12 months post-intervention

Treatment Details

Interventions

  • EMPOWER (Behavioral Intervention)
  • Supportive Conversation (Other)
Trial OverviewThe study tests if the EMPOWER program better reduces symptoms of grief and PTSD in surrogates compared to just having supportive conversations. It also looks at depression, regrets, and how well patient care matches their values over time.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: EMPOWER armExperimental Treatment1 Intervention
The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone. Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone.
Group II: Supportive Conversation armPlacebo Group1 Intervention
The Supportive Conversation (SC) arm includes a supportive, empathic encounter without specific skill-building for approximately the same amount of time as EMPOWER. Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after SC within 3 months conducted in person and by phone.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Weill Medical College of Cornell University

Lead Sponsor

Trials
1,103
Recruited
1,157,000+
Dr. Robert Min profile image

Dr. Robert Min

Weill Medical College of Cornell University

Chief Executive Officer since 2024

MD, MBA

Dr. Adam R. Stracher profile image

Dr. Adam R. Stracher

Weill Medical College of Cornell University

Chief Medical Officer since 2024

MD

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+
Dr. Jeanne Marrazzo profile image

Dr. Jeanne Marrazzo

National Institutes of Health (NIH)

Chief Medical Officer

MD from University of California, Los Angeles

Dr. Jay Bhattacharya profile image

Dr. Jay Bhattacharya

National Institutes of Health (NIH)

Chief Executive Officer

MD, PhD from Stanford University

National Institute of Nursing Research (NINR)

Collaborator

Trials
623
Recruited
10,400,000+
Dr. Jessica Gill profile image

Dr. Jessica Gill

National Institute of Nursing Research (NINR)

Chief Medical Officer since 2023

PhD in Nursing from Johns Hopkins University

Dr. Shannon Zenk profile image

Dr. Shannon Zenk

National Institute of Nursing Research (NINR)

Chief Executive Officer since 2020

PhD in Urban Planning and Policy Development from Rutgers University

Findings from Research

The COPE program, an educational-behavioral intervention for mothers of critically ill children, significantly reduced parental stress and improved participation in their children's care, leading to better emotional outcomes for both mothers and children.
Children whose mothers participated in the COPE program exhibited fewer behavioral problems and adjustment issues up to 12 months after discharge compared to those in the control group, suggesting that early intervention can help mitigate long-term mental health risks.
Creating opportunities for parent empowerment: program effects on the mental health/coping outcomes of critically ill young children and their mothers.Melnyk, BM., Alpert-Gillis, L., Feinstein, NF., et al.[2022]
The COPE program significantly improved mothers' ability to support their critically ill children during medical procedures, leading to better emotional support and reduced parental stress.
Mothers who participated in the COPE program reported fewer post-traumatic stress symptoms and less change in their parental roles four weeks after their child's hospitalization, highlighting the program's effectiveness in helping families cope with the stress of critical illness.
Helping mothers cope with a critically ill child: a pilot test of the COPE intervention.Melnyk, BM., Alpert-Gillis, LJ., Hensel, PB., et al.[2019]
The EMPOWER intervention, a cognitive-behavioral and acceptance-based program, aims to improve mental health outcomes for surrogate decision-makers in the ICU, addressing their peritraumatic stress and potentially enhancing the quality of life for patients.
The study will evaluate the effectiveness of EMPOWER through a randomized controlled trial involving 60 participants, assessing its impact on mental health symptoms and patient care outcomes, with feedback from clinicians and caregivers used to refine the intervention.
Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience (EMPOWER) among Surrogate Decision-Makers of ICU Patients: study protocol for a randomized controlled trial.Prigerson, HG., Viola, M., Brewin, CR., et al.[2021]

References

Creating opportunities for parent empowerment: program effects on the mental health/coping outcomes of critically ill young children and their mothers. [2022]
Development and preliminary evaluation of EMPOWER for surrogate decision-makers of critically ill patients. [2022]
Helping mothers cope with a critically ill child: a pilot test of the COPE intervention. [2019]
Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience (EMPOWER) among Surrogate Decision-Makers of ICU Patients: study protocol for a randomized controlled trial. [2021]
Nurses' Empowerment Scale for ICU patients' families: an instrument development study. [2019]
Survivors of Critical Illness and Their Relatives. A Qualitative Study on Hospital Discharge Experience. [2020]
Healthcare delivery and recovery after critical illness. [2023]
Family health conversations versus support group conversations when a family member has been critically ill: A mixed methods study. [2021]
Optimizing Critical Illness Recovery: Perspectives and Solutions From the Caregivers of ICU Survivors. [2022]
What is supportive when an adult next-of-kin is in critical care? [2022]